Estudio de la biodegradabilidad y ecotoxicidad de plásticos oxodegradables de mayor uso en Colombia

211 páginas. Doctorado en Ciencias e Ingeniería Ambientales.El polietileno es ampliamente utilizado en envases debido a su estabilidad química, ligereza, impermeabilidad y bajo costo. Sin embargo, estas propiedades se convierten en problemas cuando el material se descarta. Los plásticos oxodegradables (significando que son materiales con aditivos prooxidantes o prodegradantes), que se degradan por un proceso abiótico-biótico, han sido promovidos como una solución a la contaminación causada por los plásticos. Esta investigación evalúa la degradabilidad del polietileno de alta densidad convencional y oxodegradable en ambientes tropicales marinos y de agua dulce. Las muestras de estos plásticos, con y sin degradación abiótica previa, fueron expuestas a la intemperización directa, en el Mar Caribe y el Río Magdalena, en Colombia. Su degradación se evaluó durante seis meses mediante la formación de grupos carbonilo, disminución en el porcentaje de elongación a la ruptura y evidencia visual de deterioro. Se observó una degradación más rápida en las condiciones marinas, evidenciando que la salinidad, la presencia de microorganismos, la radiación ultravioleta natural y la temperatura son los promotores más relevantes de la degradación, especialmente para los plásticos oxodegradables, como lo demuestra el aumento del índice de carbonilo. Todos los especímenes mostraron formación de biopelícula o depósito microbiano, en algunos casos grietas y fragmentación, especialmente en ejemplares de polietileno de alta densidad oxidados en el medio marino. Se observó que los plásticos oxodegradables, y en menor grado los convencionales, iniciaron su proceso de degradación, en términos de pérdida completa de sus propiedades mecánicas, sin embargo no lograron una completa desintegración o mineralización. En este sentido se puede afirmar que los plásticos oxodegradables se degradan más rápidamente que los plásticos convencionales en condiciones naturales, debido fundamentalmente a la presencia de aditivo prodegradante, sin embargo este aditivo no garantiza la mineralización del material. Si bien es cierto que la degradación ocurrió en condiciones naturales, la biodegradación no se logró en condiciones controladas de laboratorio debido a que la prueba respirométrica no fue contundente para determinar la biodegradabilidad de los materiales. Se debe añadir que los materiales ensayados en pruebas controladas en laboratorio mostraron que no son tóxicos para el microorganismo Chlorella sp, lo cual no significa que la presencia de plásticos en ambientes naturales no produzca impactos adversos. Por tanto sólo se podrá evitar el daño ocasionado por los plásticos si se implementan políticas públicas y medidas que conduzcan a desestimular el consumo logrando un uso racional de los plásticos y una disposición adecuada de los residuos.Polyethylene is widely used in packaging due to its chemical stability, lightness, impermeability and low cost. However, these properties become problems when the material is discarded. Oxodegradable plastics, which are degraded by an abiotic-biotic process, have been promoted as a solution to the pollution caused by plastics. This research evaluates the degradability of conventional and oxodegradable high density polyethylene in tropical marine and freshwater environments. Samples of these plastics, with and without previous abiotic degradation, were exposed to direct weathering in the Caribbean Sea and the Magdalena River in Colombia. Its degradation was evaluated during six months by formation of carbonyl groups, decrease in the percentage of elongation at break and visual evidence of deterioration. A faster degradation was observed in the marine conditions, evidencing that salinity, presence of microorganisms, natural UV radiation and temperature are the most important promoters of degradation, especially for the oxodegradable plastics, as evidenced by the increase of carbonyl index. All specimens showed biofilm formation, in some cases cracking and fragmentation; especially in high-density polyethylene (HDPE) oxidized in the marine environment. It was observed that the oxodegradable plastics and, to a lesser extent, conventional plastics, began their degradation process, in terms of complete loss of their mechanical properties, but did not achieve complete disintegration or mineralization. In this sense it can be affirmed that oxodegradable plastics degrade more rapidly under natural conditions, mainly due to the presence of a pro-oxidant, however this additive does not guarantee complete mineralization of the material. Although it is true that the degradation occurred under natural conditions, biodegradation was not achieved under controlled laboratory conditions because the respirometric test was not conclusive to determine the biodegradability of the materials. It should be added that the tested showed that they are not toxic to the microorganism Chlorella sp. However, this does not mean that the presence of plastics in natural environments does not produce adverse impacts. Therefore, damage can only be avoided if measures that lead to an adequate disposal of plastic wastes under controlled conditions are implementedConsejo Nacional de Ciencia y Tecnología (México)

Molecular Bases of Catalysis and ADP-Ribose Preference of Human Mn2+-Dependent ADP-Ribose/CDP-Alcohol Diphosphatase and Conversion by Mutagenesis to a Preferential Cyclic ADP-Ribose Phosphohydrolase

Among metallo-dependent phosphatases, ADP-ribose/CDP-alcohol diphosphatases form a protein family (ADPRibase-Mn-like) mainly restricted, in eukaryotes, to vertebrates and plants, with preferential expression, at least in rodents, in immune cells. Rat and zebrafish ADPRibase-Mn, the only biochemically studied, are phosphohydrolases of ADP-ribose and, somewhat less efficiently, of CDP-alcohols and 2´,3´-cAMP. Furthermore, the rat but not the zebrafish enzyme displays a unique phosphohydrolytic activity on cyclic ADP-ribose. The molecular basis of such specificity is unknown. Human ADPRibase-Mn showed similar activities, including cyclic ADP-ribose phosphohydrolase, which seems thus common to mammalian ADPRibase-Mn. Substrate docking on a homology model of human ADPRibase-Mn suggested possible interactions of ADP-ribose with seven residues located, with one exception (Cys253), either within the metallo-dependent phosphatases signature (Gln27, Asn110, His111), or in unique structural regions of the ADPRibase-Mn family: s2s3 (Phe37 and Arg43) and h7h8 (Phe210), around the active site entrance. Mutants were constructed, and kinetic parameters for ADP-ribose, CDP-choline, 2´,3´-cAMP and cyclic ADP-ribose were determined. Phe37 was needed for ADP-ribose preference without catalytic effect, as indicated by the increased ADP-ribose Km and unchanged kcat of F37A-ADPRibase-Mn, while the Km values for the other substrates were little affected. Arg43 was essential for catalysis as indicated by the drastic efficiency loss shown by R43A-ADPRibase-Mn. Unexpectedly, Cys253 was hindering for cADPR phosphohydrolase, as indicated by the specific tenfold gain of efficiency of C253A-ADPRibase-Mn with cyclic ADP-ribose. This allowed the design of a triple mutant (F37A+L196F+C253A) for which cyclic ADP-ribose was the best substrate, with a catalytic efficiency of 3.5´104 M-1s-1 versus 4´103 M-1s-1 of the wild type.info:eu-repo/semantics/publishedVersio

The characterization of Escherichia coli CpdB as a recombinantpProtein reveals that, besides having the expected 3´-nucleotidase and 2´,3´-cyclic mononucleotide phosphodiesterase activities, it is also active as cyclic dinucleotide phosphodiesterase

Endogenous cyclic diadenylate phosphodiesterase activity was accidentally detected in lysates of Escherichia coli BL21. Since this kind of activity is uncommon in Gram-negative bacteria, its identification was undertaken. After partial purification and analysis by denaturing gel electrophoresis, renatured activity correlated with a protein identified by fingerprinting as CpdB (cpdB gene product), which is annotated as 3´-nucleotidase / 2´,3´- cyclicmononucleotide phosphodiesterase, and it is synthesized as a precursor protein with a signal sequence removable upon export to the periplasm. It has never been studied as a recombinant protein. The coding sequence of mature CpdB was cloned and expressed as a GST fusion protein. The study of the purified recombinant protein, separated from GST, confirmed CpdB annotation. The assay of catalytic efficiencies (kcat/Km) for a large substrate set revealed novel CpdB features, including very high efficiencies for 3´-AMP and 2´,3´- cyclic mononucleotides, and previously unknown activities on cyclic and linear dinucleotides. The catalytic efficiencies of the latter activities, though low in relative terms when compared to the major ones, are far from negligible. Actually, they are perfectly comparable to those of the ‘average’ enzyme and the known, bona fide cyclic dinucleotide phosphodiesterases. On the other hand, CpdB differs from these enzymes in its extracytoplasmic location and in the absence of EAL, HD and DHH domains. Instead, it contains the domains of the 5´-nucleotidase family pertaining to the metallophosphoesterase superfamily, although CpdB lacks 5´-nucleotidase activity. The possibility that the extracytoplasmic activity of CpdB on cyclic dinucleotides could have physiological meaning is discussed.Trabajo financiado por: Junta de Extremadura y Fondos FEDER. Ayudas GR10133 y GR15143 Donación privada para María Jesús Costas Vázquez. Contrato 2015/00481/001peerReviewe

Molecular bases of catalysis and ADP-ribose preference of human Mn2+-dependent ADP-ribose/CDP-alcohol diphosphatase and conversion by mutagenesis to a preferential cyclic ADP-ribose phosphohydrolase

Entre las fosfatasas métalo-dependientes, ADP-ribosa/CDP-alcohol diphosphatases forman una familia de proteínas (ADPRibase-Mn-like) principalmente restringida, en eucariotas, vertebrados y plantas, con expresión preferencial, al menos en roedores, en células inmunológicas. La rata y el pez cebra, el único Ribase-Mn ADP bioquímicamente estudiados, son ADP-ribosa phosphohydrolases y algo menos eficiente, de CDP-alcoholes y 2',3'-cAMP. Además, la rata, pero no el pez cebra, muestra una única enzima con actividad ADP-ribosa phosphohydrolytic cíclica. La base molecular de tal especificidad es desconocida. Las ADPRibase-Mn de humanos mostraron actividades similares, incluyendo ADP-ribosa phosphohydrolase cíclica, lo que parece común a los mamíferos Ribase-Mn ADP. Acoplamiento del sustrato en un modelo de homología de ADPRibase-Mn de humanos sugiere posibles interacciones de ADP-ribosa con siete residuos ubicado, con una sola excepción (Cys253), ya sea dentro de la metalo-fosfatasas dependientes de la firma (Gln27, Asn110, Su111), o en regiones estructurales exclusivos de la familia ADPRibase-Mn: s2s3 (PHE37 y Arg43) y h7h8 (Phe210), alrededor de la entrada del sitio activo. Se construyeron mutantes y parámetros cinéticos para ADP-ribosa, CDP-colina, 2',3'-cAMP y cíclica de ADP-ribosa fueron determinadas. Phe37 fue necesaria para ADP-ribosa preferencia sin efecto catalítico, según lo indicado por el aumento de la ADP-ribosa Km y kcat invariable de F37A-ADPRibase-Mn Km, mientras que los valores para los otros sustratos apenas se vieron afectadas. Arg43 era esencial para la catálisis como indicado por la drástica pérdida de eficacia demostrada por R43A-ADPRibase-Mn. Inesperadamente, Cys253 obstaculizaba para cADPR phosphohydrolase, según lo indicado por las diez veces la ganancia de eficiencia de C253A-ADPRibase-Mn con ADP-ribosa cíclica. Esto permitió el diseño de un mutante triple (F37A L196F C253A) para que ADP-ribosa cíclica era el mejor sustrato, con una eficiencia catalítica de 3,5'104 M-1s-1 versus 4'103 M-1s-1 del tipo salvaje.Among metallo-dependent phosphatases, ADP-ribose/CDP-alcohol diphosphatases form a protein family (ADPRibase-Mn-like) mainly restricted, in eukaryotes, to vertebrates and plants, with preferential expression, at least in rodents, in immune cells. Rat and zebrafish ADPRibase-Mn, the only biochemically studied, are phosphohydrolases of ADP-ribose and, somewhat less efficiently, of CDP-alcohols and 2´,3´-cAMP. Furthermore, the rat but not the zebrafish enzyme displays a unique phosphohydrolytic activity on cyclic ADP-ribose. The molecular basis of such specificity is unknown. Human ADPRibase-Mn showed similar activities, including cyclic ADP-ribose phosphohydrolase, which seems thus common to mammalian ADPRibase-Mn. Substrate docking on a homology model of human ADPRibase-Mn suggested possible interactions of ADP-ribose with seven residues located, with one exception (Cys253), either within the metallo-dependent phosphatases signature (Gln27, Asn110, His111), or in unique structural regions of the ADPRibase-Mn family: s2s3 (Phe37 and Arg43) and h7h8 (Phe210), around the active site entrance. Mutants were constructed, and kinetic parameters for ADP-ribose, CDP-choline, 2´,3´-cAMP and cyclic ADP-ribose were determined. Phe37 was needed for ADP-ribose preference without catalytic effect, as indicated by the increased ADP-ribose Km and unchanged kcat of F37A-ADPRibase-Mn, while the Km values for the other substrates were little affected. Arg43 was essential for catalysis as indicated by the drastic efficiency loss shown by R43A-ADPRibase-Mn. Unexpectedly, Cys253 was hindering for cADPR phosphohydrolase, as indicated by the specific tenfold gain of efficiency of C253A-ADPRibase-Mn with cyclic ADP-ribose. This allowed the design of a triple mutant (F37A+L196F+C253A) for which cyclic ADP-ribose was the best substrate, with a catalytic efficiency of 3.5´104 M-1s-1 versus 4´103 M-1s-1 of the wild type.Trabajo patrocinado por: Ministerio de Ciencia e Innovación. Proyecto BFU2009-07296 (I+D+i) Junta de Extremadura. Proyecto GRU09135 y GR10133 Cofinanciación por el Fondo Europeo de Desarrollo Regional y Fondo Social EuropeopeerReviewe

Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018 population-based measurement studies with 88.6 million participants

© The Author(s) 2018. Background: Change in the prevalence of raised blood pressure could be due to both shifts in the entire distribution of blood pressure (representing the combined effects of public health interventions and secular trends) and changes in its high-blood-pressure tail (representing successful clinical interventions to control blood pressure in the hypertensive population). Our aim was to quantify the contributions of these two phenomena to the worldwide trends in the prevalence of raised blood pressure. Methods: We pooled 1018 population-based studies with blood pressure measurements on 88.6 million participants from 1985 to 2016. We first calculated mean systolic blood pressure (SBP), mean diastolic blood pressure (DBP) and prevalence of raised blood pressure by sex and 10-year age group from 20-29 years to 70-79 years in each study, taking into account complex survey design and survey sample weights, where relevant. We used a linear mixed effect model to quantify the association between (probittransformed) prevalence of raised blood pressure and age-group- and sex-specific mean blood pressure. We calculated the contributions of change in mean SBP and DBP, and of change in the prevalence-mean association, to the change in prevalence of raised blood pressure. Results: In 2005-16, at the same level of population mean SBP and DBP, men and women in South Asia and in Central Asia, the Middle East and North Africa would have the highest prevalence of raised blood pressure, and men and women in the highincome Asia Pacific and high-income Western regions would have the lowest. In most region-sex-age groups where the prevalence of raised blood pressure declined, one half or more of the decline was due to the decline in mean blood pressure. Where prevalence of raised blood pressure has increased, the change was entirely driven by increasing mean blood pressure, offset partly by the change in the prevalence-mean association. Conclusions: Change in mean blood pressure is the main driver of the worldwide change in the prevalence of raised blood pressure, but change in the high-blood-pressure tail of the distribution has also contributed to the change in prevalence, especially in older age groups

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants

Summary Background Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents. Methods For this pooled analysis, we used a database of cardiometabolic risk factors collated by the Non-Communicable Disease Risk Factor Collaboration. We applied a Bayesian hierarchical model to estimate trends from 1985 to 2019 in mean height and mean BMI in 1-year age groups for ages 5–19 years. The model allowed for non-linear changes over time in mean height and mean BMI and for non-linear changes with age of children and adolescents, including periods of rapid growth during adolescence. Findings We pooled data from 2181 population-based studies, with measurements of height and weight in 65 million participants in 200 countries and territories. In 2019, we estimated a difference of 20 cm or higher in mean height of 19-year-old adolescents between countries with the tallest populations (the Netherlands, Montenegro, Estonia, and Bosnia and Herzegovina for boys; and the Netherlands, Montenegro, Denmark, and Iceland for girls) and those with the shortest populations (Timor-Leste, Laos, Solomon Islands, and Papua New Guinea for boys; and Guatemala, Bangladesh, Nepal, and Timor-Leste for girls). In the same year, the difference between the highest mean BMI (in Pacific island countries, Kuwait, Bahrain, The Bahamas, Chile, the USA, and New Zealand for both boys and girls and in South Africa for girls) and lowest mean BMI (in India, Bangladesh, Timor-Leste, Ethiopia, and Chad for boys and girls; and in Japan and Romania for girls) was approximately 9–10 kg/m2. In some countries, children aged 5 years started with healthier height or BMI than the global median and, in some cases, as healthy as the best performing countries, but they became progressively less healthy compared with their comparators as they grew older by not growing as tall (eg, boys in Austria and Barbados, and girls in Belgium and Puerto Rico) or gaining too much weight for their height (eg, girls and boys in Kuwait, Bahrain, Fiji, Jamaica, and Mexico; and girls in South Africa and New Zealand). In other countries, growing children overtook the height of their comparators (eg, Latvia, Czech Republic, Morocco, and Iran) or curbed their weight gain (eg, Italy, France, and Croatia) in late childhood and adolescence. When changes in both height and BMI were considered, girls in South Korea, Vietnam, Saudi Arabia, Turkey, and some central Asian countries (eg, Armenia and Azerbaijan), and boys in central and western Europe (eg, Portugal, Denmark, Poland, and Montenegro) had the healthiest changes in anthropometric status over the past 3·5 decades because, compared with children and adolescents in other countries, they had a much larger gain in height than they did in BMI. The unhealthiest changes—gaining too little height, too much weight for their height compared with children in other countries, or both—occurred in many countries in sub-Saharan Africa, New Zealand, and the USA for boys and girls; in Malaysia and some Pacific island nations for boys; and in Mexico for girls. Interpretation The height and BMI trajectories over age and time of school-aged children and adolescents are highly variable across countries, which indicates heterogeneous nutritional quality and lifelong health advantages and risks

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities(.)(1,2) This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity(3-6). Here we use 2,009 population-based studies, with measurements of height and weight in more than 112 million adults, to report national, regional and global trends in mean BMI segregated by place of residence (a rural or urban area) from 1985 to 2017. We show that, contrary to the dominant paradigm, more than 55% of the global rise in mean BMI from 1985 to 2017-and more than 80% in some low- and middle-income regions-was due to increases in BMI in rural areas. This large contribution stems from the fact that, with the exception of women in sub-Saharan Africa, BMI is increasing at the same rate or faster in rural areas than in cities in low- and middle-income regions. These trends have in turn resulted in a closing-and in some countries reversal-of the gap in BMI between urban and rural areas in low- and middle-income countries, especially for women. In high-income and industrialized countries, we noted a persistently higher rural BMI, especially for women. There is an urgent need for an integrated approach to rural nutrition that enhances financial and physical access to healthy foods, to avoid replacing the rural undernutrition disadvantage in poor countries with a more general malnutrition disadvantage that entails excessive consumption of low-quality calories.Peer reviewe

Trayectorias de un viaje por la investigación educativa desde el sentipensar de los maestros y maestras : experiencias en desarrollo del programa de pensamiento crítico

428 páginasEste libro reúne 19 experiencias que continúan el acompañamiento en la fundamentación, desarrollo y estructuración de estrategias de tipo pedagógico y didáctico dentro de la ruta sentipensante en el Nivel II: Experiencias en desarrollo. Igualmente, en estas experiencias se hace una ampliación de referentes, técnicas e instrumentos para recoger información de los 19 textos presentados. De tal manera, estas experiencias son fruto de este acompañamiento que ha realizado el Instituto para la Investigación Educativa y el Desarrollo Pedagógico IDEP, que servirán de base y referente para seguir aportando en la configuración y consolidación de comunidades de saber y práctica pedagógica, así como en la conformación de colectivos y redes de maestros y maestras

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings